Cardiovascular Medications
Browse the full catalog when you want to compare more medications, prices, and available options.
Cardiovascular treatment is broader than lowering a number on a blood-pressure monitor. Physicians may be preventing stroke, reducing the workload of a weakened heart, controlling an abnormal rhythm, managing angina or lowering cholesterol to reduce future vascular events. These purposes can coexist, but a medicine that is beneficial for one does not automatically carry the same indication in another. The first question about a cardiovascular product should therefore be why it was prescribed, followed by what the clinician intends to monitor.
The Mexican Ensanut 2022 investigation measured blood pressure in thousands of adults and found a hypertension prevalence of 47.8% under the ACC/AHA definition, with many affected people unaware of the diagnosis. Its authors also showed how the prevalence changes when another diagnostic threshold is used. This is a reminder that one elevated reading after exercise or stress should be interpreted in context, while consistently high readings deserve attention even when the patient feels entirely well.
The medicines within this category work at different points in the circulation. ACE inhibitors such as lisinopril influence the renin-angiotensin system, while losartan and valsartan block angiotensin II receptors. Beta blockers, including metoprolol and carvedilol, vary in the receptors they affect and in their roles for particular cardiac conditions. Verapamil affects calcium channels and electrical conduction, so it can interact with medicines that also slow heart rate. Atorvastatin reduces LDL cholesterol through a separate pathway and is not a replacement for blood-pressure treatment.
For patients taking several of these medicines, formulation and timing may be as important as the ingredient. Immediate-release and extended-release metoprolol products, for example, are not administered on identical schedules. Diuretics may influence fluid and electrolyte balance, and medicines acting on the renin-angiotensin system may require monitoring of kidney function and potassium. A new dizzy spell could reflect low blood pressure, a slow pulse, dehydration or another cause, each of which requires a different response.
Cholesterol management is another area where the reason for treatment affects the target. A person who has already experienced a heart attack may need a different intensity of LDL lowering from someone receiving primary prevention. Medication adherence, laboratory response and the risk of adverse effects are reviewed together, rather than using a single normal cholesterol result as permission to stop treatment.
Long-term cardiovascular care often includes smoking cessation, activity, dietary changes and review of diabetes control, but established disease may still require medication even when habits improve. Patients should not stop a prescribed drug simply because their readings look better, since treatment may be responsible for that improvement. The product listings allow comparison of names and presentations, with changes of dose or class reserved for a clinician who can consider the whole cardiovascular history.









